6-K 1 d777541d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2019

Commission File Number                         

 

 

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

 

 

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☑             Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  ☐     No  ☑

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

 

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

Kate Hill

Kate Hill

Company Secretary

Date 22 July 2019


LOGO

ASX RELEASE

22 July 2019

KAZIA TO TEST GDC-0084 WITH RADIOTHERAPY IN PHASE I CLINICAL TRIAL

AT LEADING US CANCER CENTER

Sydney, 22 July 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia’s investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain (brain metastases and leptomeningeal metastases). This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.

Dr James Garner, Chief Executive Officer of Kazia Therapeutics commented, “MSK is one of the world’s leading cancer treatment centers, and we are privileged to be supporting them in this state-of-the-art project. Many cancers have the potential to spread to the brain, and they become very difficult to treat when they do. The work being done at MSK will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy, which remains the current standard of care in most cases.”

Key Points

 

   

MSK will initiate a phase I clinical trial of GDC-0084 in combination with radiotherapy for patients with solid tumor brain metastases (cancer that has spread to the brain) and leptomeningeal metastases that harbors a genetic alteration in the PI3K pathway.

 

   

The trial is expected to recruit 18-30 patients and will take about two years to complete.

 

   

The trial will be led by MSK, with Kazia providing support including study drug and a financial grant.

 

   

Initiation of this study brings to five the total number of ongoing clinical trials with GDC-0084, each in different forms of brain cancer.

Up to 30% of patients with metastatic cancer will develop secondary tumors (metastases) in the brain. Radiotherapy remains the standard of care, but 30-50% of patients will progress within one year, despite best available treatment. In animal models of certain cancers, activation of the PI3K pathway has been shown to contribute to radiotherapy resistance. GDC-0084 is a PI3K inhibitor that can cross the blood-brain barrier, and as such it may be able to reduce the problem of resistance to radiotherapy. This clinical trial has been developed to test that hypothesis.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director


The trial is expected to recruit 18-30 patients, all of whom will have cancer that has spread to the brain. Patients will be genetically tested for a specific alteration in the PI3K pathway, and only those with a relevant mutation will be enrolled. This is an example of an approach to clinical research that is sometimes referred to as ‘precision medicine’ or ‘personalized medicine’, in which treatments are carefully targeted to those patients most likely to benefit. It is expected that the trial will begin recruitment in the second half of calendar 2019.

The study in two parts. The first part will aim to determine the maximum tolerated dose (MTD) of GDC-0084 when given together with radiotherapy. Once that dose has been determined, the second part of the study will enroll an additional twelve patients at that dose to explore preliminary signals of efficacy.

The Principal Investigator for the study is Dr T Jonathan Yang, Director of Metastatic Disease Program in MSK’s Department of Radiation Oncology. Dr Yang is a graduate of Yale University School of Medicine and a Board-certified radiation oncologist, with a specialist interest in treating tumors of the central nervous system. He is an extensively-published clinical researcher who has participated in a substantial number of clinical trials in brain cancer.

The initiation of the study brings to five the number of ongoing clinical trials with GDC-0084:-

 

Sponsor

   Phase   

Indication

   Registration

Kazia Therapeutics

   II    Glioblastoma    NCT03522298

Alliance for Clinical Trials in Oncology

   II    Brain metastases    NCT03994796

Dana-Farber Cancer Institute

   II   

Breast cancer brain metastases

(with Herceptin)

   NCT03765983

St Jude Children’s Research Hospital

   I    DIPG (childhood brain cancer)    NCT03696355

Memorial Sloan Kettering Cancer Center

   I   

Brain metastases

(with radiotherapy)

   (TBA)

It is expected that the study will take approximately two years to complete. Kazia will provide support, including a financial grant for a portion of the costs. The study will be conducted under an ‘investigator IND’ with the US FDA, in which the primary regulatory responsibilities for the study will be assumed by MSK. Implementation of the study is conditional upon approval from the Institutional Review Board at MSK, and this approval has yet to be obtained.

[ENDS]


About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.